Alcobra Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
27
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
- Investments
-
1
Alcobra General Information
Description
Developer of a proprietary drug for disabled care patients intended to become a leading global player in the pharmaceutical industry through disruptive efficiency and innovation. The company's pharmaceutical operations are focused on the development of new medications to help patients with cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome.
Contact Information
Website
www.alcobra-pharma.comCorporate Office
- Azrieli Triangle Building
- 39th Floor 132 Derech Menachem Begin
- Tel Aviv 6701101
- Israel
Corporate Office
- Azrieli Triangle Building
- 39th Floor 132 Derech Menachem Begin
- Tel Aviv 6701101
- Israel
Alcobra Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alcobra Comparisons
Industry
Financing
Details
Alcobra Competitors (20)
One of Alcobra’s 20 competitors is Marinus Pharmaceuticals, a Private Equity-Backed company based in Radnor, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marinus Pharmaceuticals | Private Equity-Backed | Radnor, PA | ||||
| H. Lundbeck | Corporation | Copenhagen, Denmark | ||||
| Promentis Pharmaceuticals | Venture Capital-Backed | Milwaukee, WI | ||||
| Tris Pharma | Private Debt Financed | Monmouth Junction, NJ | ||||
| Enzon Pharmaceuticals | Corporation | Cranford, NJ |
Alcobra Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alcobra Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alcobra Acquisitions (1)
Alcobra’s most recent deal was a Reverse Merger with Arcturus Therapeutics. The deal was made on 16-Nov-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Arcturus Therapeutics | 16-Nov-2017 | Reverse Merger | Drug Discovery |
Alcobra Exits (1)
Alcobra’s most recent exit was on 16-Nov-2017 from Arcturus Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Arcturus Therapeutics | 16-Nov-2017 | Completed |
|
Alcobra FAQs
-
When was Alcobra founded?
Alcobra was founded in 2008.
-
Where is Alcobra headquartered?
Alcobra is headquartered in Tel Aviv, Israel.
-
What is the size of Alcobra?
Alcobra has 27 total employees.
-
What industry is Alcobra in?
Alcobra’s primary industry is Pharmaceuticals.
-
Is Alcobra a private or public company?
Alcobra is a Private company.
-
What is the current valuation of Alcobra?
The current valuation of Alcobra is .
-
What is Alcobra’s current revenue?
The current revenue for Alcobra is .
-
How much funding has Alcobra raised over time?
Alcobra has raised $58M.
-
Who are Alcobra’s investors?
Brosh Capital Partners, Hadasit Bio-Holdings, and Knoll Capital Management have invested in Alcobra.
-
Who are Alcobra’s competitors?
Marinus Pharmaceuticals, H. Lundbeck, Promentis Pharmaceuticals, Tris Pharma, and Enzon Pharmaceuticals are some of the 20 competitors of Alcobra.
-
When was Alcobra acquired?
Alcobra was acquired on 16-Nov-2017.
-
Who acquired Alcobra?
Alcobra was acquired by Arcturus Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
